{"product_id":"ikanggroup-swot-analysis","title":"iKang Group SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp group combines strong brand recognition in china pediatric and family health segments with a growing digital services footprint yet faces regulatory scrutiny margin pressure from intense competition full swot unpacks these dynamics quantifies financial impact maps strategic options for investors operators.\u003e\n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominant Market Position and Brand Recognition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiKang Group holds the largest share among China’s private preventive healthcare chains, serving over 20 million customers by FY2024 and operating 1,100+ service locations, which makes the brand widely recognized for quality.\u003c\/p\u003e\n\u003cp\u003eThat reputation lets iKang charge premiums roughly 15–25% above local clinics for executive physicals and advanced screenings, supporting higher gross margins (FY2024 gross margin ~38%).\u003c\/p\u003e\n\u003cp\u003eStrong brand equity, national scale, and established referral partnerships create a high barrier to entry in the high-end segment, limiting disruption from smaller rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced AI and Digital Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eiKang’s iKang AI plus uses AI trained on over 25 million annual checkup records (2024 internal report) to lift diagnostic accuracy; pilot studies reported a 12–18% reduction in false positives for imaging-based screens. Leveraging big data across 240+ centers, the platform generates finer risk stratification and personalized follow-ups, strengthening appeal to tech-savvy urban consumers and supporting higher per-visit revenue and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Corporate Client Base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiKang Health Group (iKang) serves an extensive B2B roster, including dozens of Fortune 500 firms in China, which accounted for roughly 62% of its 2024 service revenue, giving predictable, recurring cash flows.\u003c\/p\u003e\n\u003cp\u003eLong-term corporate contracts deliver retention rates above 85% and multi-year agreements; customized employee health packages drive higher per-client ARPU and reduce churn.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Nationwide Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpwith medical centers in over chinese cities as of dec ikang group delivers unmatched nationwide reach letting it serve large employers with multi-province staff efficiently.\u003e\n\u003cpthis scale supports centralized contracts and bulk purchasing reported rmb billion in procurement savings fy2024 boosting margins equipment upgrade cycles.\u003e\n\u003cpthe network also strengthens referral flows and brand recognition lifting outpatient visits to million in reducing per-visit marketing cost.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e400+ centers, 60+ cities (Dec 2025)\u003c\/li\u003e\n\u003cli\u003e18M outpatient visits (2024)\u003c\/li\u003e\n\u003cli\u003eRMB 1.2B procurement savings (FY2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pthis\u003e\u003c\/pwith\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-End Service Differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eiKang targets the premium preventive-care niche with personalized packages, not mass-market checkups, driving higher ASPs (average selling price) and better margins; in 2024 the company reported a 28% gross margin in premium service lines versus ~15% in basic screening segments industry-wide.\u003c\/p\u003e\n\u003cp\u003eThe group offers advanced cardiovascular and oncology screening—CT coronary angiography, low-dose CT for lung cancer, PET-CT—for higher diagnostic yield and cross-sell; premium customers generate ~60% more revenue per visit.\u003c\/p\u003e\n\u003cp\u003eThis high-end focus shields iKang from lower-tier price wars and helped sustain revenue growth of 12% YoY in 2024 despite broader industry pricing pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium focus → higher ASPs, 28% gross margin\u003c\/li\u003e\n\u003cli\u003eAdvanced imaging: CT, PET-CT, low-dose CT\u003c\/li\u003e\n\u003cli\u003ePremium patients = ~60% more revenue\/visit\u003c\/li\u003e\n\u003cli\u003eResilient: 12% revenue growth YoY 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eiKang: China’s preventive-care leader — 400+ centers, 20M customers, 38% gross margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiKang leads China’s private preventive care with 400+ centers in 60+ cities (Dec 2025), 18M outpatient visits (2024), 20M customers by FY2024, FY2024 gross margin ~38%, RMB1.2B procurement savings, 62% revenue from B2B, 85%+ corporate retention, and premium services driving ~28% gross margin and 12% YoY revenue growth (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCenters\/cities\u003c\/td\u003e\n\u003ctd\u003e400+\/60+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient visits\u003c\/td\u003e\n\u003ctd\u003e18M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers\u003c\/td\u003e\n\u003ctd\u003e20M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~38% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement savings\u003c\/td\u003e\n\u003ctd\u003eRMB1.2B (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eB2B revenue\u003c\/td\u003e\n\u003ctd\u003e62% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorporate retention\u003c\/td\u003e\n\u003ctd\u003e85%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue growth\u003c\/td\u003e\n\u003ctd\u003e12% YoY (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of iKang Group, highlighting its core strengths and weaknesses, key market opportunities, and external threats to inform strategic decision-making and competitive positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix for iKang Group to quickly align strategic decisions and communicate strengths, weaknesses, opportunities, and threats to stakeholders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Capital Expenditure and Operational Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp maintaining and expanding ikang healthcare group clinics requires heavy capital: as of fy2024 the company reported over rmb billion in property plant equipment annual capex ran about million pressuring margins when utilization dips below\u003e\n\u003c\/p\u003e\n\u003cp equipment and it refresh cycles push recurring spend ikang disclosed fy2024 r investments near rmb million creating a continuous upgrade burden.\u003e\n\u003c\/p\u003e\n\u003cp high fixed costs plus lower patient throughput in fy2023 compressed operating margins with adjusted margin falling to the mid-single-digits so sustainment capex risks further volatility.\u003e\n\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVariable Service Quality Across Locations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpensuring consistent service quality across ikang group centers strains logistics staffing and supply chains raising per-center qa costs by an estimated versus peers. a single localized medical error or poor patient review can hit national nps revenue reported decline in affected regions past incidents. standardizing protocols needs intensive oversight ongoing retraining audit spend that compresses margins.\u003e\n\u003c\/pensuring\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on the Domestic Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eiKang Group generates over 95% of revenue from mainland China (2024 audited results: RMB 3.2bn of RMB 3.35bn total), so it’s highly exposed to local cycles.\u003c\/p\u003e\n\u003cp\u003eA Chinese GDP growth slowdown to 5.2% in 2024 and corporate cost-cutting can cut employer-paid health benefits, hurting demand for iKang’s corporate screening services.\u003c\/p\u003e\n\u003cp\u003eWith minimal international ops, iKang lacks geographic hedges against domestic systemic shocks, raising cash-flow and valuation volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChallenges in Retaining Specialized Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eiKang faces intense competition for qualified doctors, radiologists, and nurses in China, where public hospitals employ over 70% of specialists; in 2024 private clinics reported vacancy rates up to 18% for radiology roles.\u003c\/p\u003e\n\u003cp\u003eThe company must match public-hospital pay and offer sign-on bonuses—iKang’s 2023 staff costs rose 12% year-over-year to RMB 1.1 billion, reflecting this pressure.\u003c\/p\u003e\n\u003cp\u003eHigh turnover or shortages can delay scans, raise per-patient costs, and degrade diagnostic accuracy, directly affecting revenue and reputation.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVacancy rates: radiology ~18% (2024)\u003c\/li\u003e\n\u003cli\u003eStaff costs: +12% to RMB 1.1bn (2023)\u003c\/li\u003e\n\u003cli\u003ePublic hospitals hold \u0026gt;70% of specialists\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplex Corporate Debt Structure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpsince its privatization ikang healthcare group has carried a complex debt load net of about rmb billion at fy2023 cash runway and limiting funds for aggressive expansion or large acquisitions.\u003e\u003cphigh interest costs and refinancing needs push up the company weighted average cost of capital forcing leadership to prioritize deleveraging over strategic m\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet debt ~RMB 2.1bn (FY2023)\u003c\/li\u003e\n\u003cli\u003eLimits on M\u0026amp;A and capex\u003c\/li\u003e\n\u003cli\u003eHigh financing costs raise WACC\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phigh\u003e\u003c\/psince\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh capex, staff shortages and China concentration squeeze margins and raise cyclic risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpheavy capex and recurring it spend rmb r compress margins when utilization concentrated china revenue of in limited international footprint raise cyclic risk. staffing shortages costs to radiology vacancy net debt limiting m\u003e\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex (FY2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 600–800m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/IT (FY2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 150m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue concentration (2024)\u003c\/td\u003e\n\u003ctd\u003e95% China (RMB 3.2bn\/3.35bn)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaff costs (2023)\u003c\/td\u003e\n\u003ctd\u003eRMB 1.1bn (+12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiology vacancy (2024)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet debt (FY2023)\u003c\/td\u003e\n\u003ctd\u003eRMB 2.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/pheavy\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eiKang Group SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the entire in-depth version. You’re viewing a live excerpt of the complete, editable file that becomes available after checkout. The content shown is the real report you'll download post-purchase, structured and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752317989241,"sku":"ikanggroup-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ikanggroup-swot-analysis.png?v=1772239450","url":"https:\/\/growthsharematrix.com\/products\/ikanggroup-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}